JW Pharmaceutical acquires license of ‘emicizumab,’ innovative hemophilia A treatment
JW Pharmaceutical acquired a license of a hemophilia A treatment improved in administration convenience in Korea.
JW Pharmaceutical(CEO Sung-Kwon Han, Young-Seop Shin) announced on the 11th that it signed an exclusive license agreement of ‘emicizumab(development code: ACE910)’ in Korea with Chug...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
